This is the case of a 76-year-old man with PD-L1 negative adenocarcinoma who received Nivolumab as second-line treatment after Carboplatin-Pemetrexed, obtaining PR; at relapse he was treated with Atezolizumab achieving complete response at the 6-months scan; no irAEs were reported [131]. Here, CD274 is linked to adenocarcinoma.